6 results
The primary objectives are:- To evaluate the efficacy of IV induction regimens of ustekinumab in inducing clinical response in subjects with moderately to severely active Crohn*s disease who have failed or are intolerant to one or more tumor…
Safety and performance will be based on a comparison of overall success rates of the Barricaid ARDand either a concurrent group (nonrandomized) of control patients treated by conventional surgicalmethods (e.g., noninstrumented discectomy) at select…
The primary objectives are:- To evaluate clinical remission for the 2 subcutaneous (SC) maintenance regimens of ustekinumab in subjects with moderately to severely active Crohn*s disease induced into clinical response with ustekinumab in the…
MAIN Trial:Primary:To evaluate whether the efficacy of mirikizumab is superior to placebo in participants with Crohn's disease as assessed by- clinical response by patient reported outcome (PRO) at Week 12 andendoscopic response at Week 52-…
The primary objective is to evaluate the achievement of clinical response at Week 16 following a single IV re-induction dose of *6 mg/kg ustekinumab, compared with continuing regular SC q8w 90 mg ustekinumab administration, in participants with…
The primary objective of this trial is to quantify the incidence of AF in patients at high risk for but without previously known AF using a smartwatch wearable with a photoplethysmographic sensor and to determine if the incidence is higher compared…